Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swiss Re AG ( (CH:SREN) ) just unveiled an update.
Swiss Re has updated its Life Guide to include guidance on assessing life insurance applicants using repurposed longevity drugs like metformin and rapamycin. This update aims to help underwriters make informed decisions in light of the uncertain long-term effects of these drugs, which are gaining popularity for their potential anti-aging benefits. The Life Guide, used by over 800 insurance companies globally, now also features improved tools for assessing chronic kidney disease and prostate cancer risks, reinforcing Swiss Re’s commitment to evidence-based underwriting in a changing health landscape.
The most recent analyst rating on (CH:SREN) stock is a Hold with a CHF132.00 price target. To see the full list of analyst forecasts on Swiss Re AG stock, see the CH:SREN Stock Forecast page.
More about Swiss Re AG
The Swiss Re Group, headquartered in Zurich, Switzerland, is a leading global provider of reinsurance, insurance, and insurance-based risk transfer solutions. Established in 1863, the company operates through a network of around 70 offices worldwide, focusing on managing and anticipating risks such as natural catastrophes, climate change, aging populations, and cybercrime to enhance societal resilience and progress.
YTD Price Performance: 19.15%
Average Trading Volume: 651,583
Technical Sentiment Signal: Buy
Current Market Cap: CHF40.67B
For detailed information about SREN stock, go to TipRanks’ Stock Analysis page.